[go: up one dir, main page]

DK1877090T3 - Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf - Google Patents

Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf

Info

Publication number
DK1877090T3
DK1877090T3 DK06770019.5T DK06770019T DK1877090T3 DK 1877090 T3 DK1877090 T3 DK 1877090T3 DK 06770019 T DK06770019 T DK 06770019T DK 1877090 T3 DK1877090 T3 DK 1877090T3
Authority
DK
Denmark
Prior art keywords
trimed
methods
fusion protein
immunoglobulin fusion
immunoglobulin
Prior art date
Application number
DK06770019.5T
Other languages
English (en)
Inventor
Andrew D Weinberg
Nicholas P Morris
Carmen Peters
Original Assignee
Providence Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Providence Health System filed Critical Providence Health System
Application granted granted Critical
Publication of DK1877090T3 publication Critical patent/DK1877090T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK06770019.5T 2005-05-06 2006-05-04 Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf DK1877090T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67842005P 2005-05-06 2005-05-06
PCT/US2006/017285 WO2006121810A2 (en) 2005-05-06 2006-05-04 Trimeric ox40-immunoglobulin fusion protein and methods of use

Publications (1)

Publication Number Publication Date
DK1877090T3 true DK1877090T3 (da) 2014-04-14

Family

ID=37397109

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06770019.5T DK1877090T3 (da) 2005-05-06 2006-05-04 Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
DK13165713.2T DK2650020T3 (da) 2005-05-06 2006-05-04 Trimerisk OX40-immunglobulin-fusionsprotein og fremgangsmåder til anvendelser.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13165713.2T DK2650020T3 (da) 2005-05-06 2006-05-04 Trimerisk OX40-immunglobulin-fusionsprotein og fremgangsmåder til anvendelser.

Country Status (13)

Country Link
US (2) US20060280728A1 (da)
EP (2) EP2650020B1 (da)
AU (1) AU2006244497B2 (da)
CA (1) CA2606809C (da)
CY (2) CY1119342T1 (da)
DK (2) DK1877090T3 (da)
ES (2) ES2457067T3 (da)
HU (1) HUE029789T2 (da)
LT (1) LT2650020T (da)
PL (2) PL2650020T3 (da)
PT (2) PT2650020T (da)
SI (2) SI1877090T1 (da)
WO (1) WO2006121810A2 (da)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312700B1 (en) * 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
EP2806883B1 (en) 2012-01-25 2019-04-24 DNAtrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
US9828432B2 (en) 2012-02-06 2017-11-28 Providence Health & Services—Oregon Cancer treatment and monitoring methods using OX40 agonists
US10329350B2 (en) 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
EP2943512A4 (en) 2013-01-11 2016-06-01 California Inst Biomedical Res BOVINE FUSION ANTIBODY
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
WO2014121099A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
WO2015116178A1 (en) * 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
CN109045289A (zh) 2013-02-22 2018-12-21 库瑞瓦格股份公司 疫苗接种和抑制pd-1途径的组合
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
US10072064B2 (en) 2013-03-15 2018-09-11 Geoffrey W. Stone Composition comprised of antigen linked to a TNF superfamily ligand
EP3019531A4 (en) * 2013-07-11 2017-03-15 The California Institute for Biomedical Research Immunoglobulin fusion proteins and compositions thereof
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
US20160289645A1 (en) 2013-11-22 2016-10-06 Dnatrix, Inc. Adenovirus Expressing Immune Cell Stimulatory Receptor Agonist(s)
JP2017501167A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
CA2943834A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US10478491B2 (en) 2014-04-03 2019-11-19 Augusta University Research Institute, Inc. Methods for enhancing the efficacy of a tumor-directed immune response
WO2015183902A1 (en) * 2014-05-29 2015-12-03 Medimmune, Llc Ox40l fusion proteins and uses thereof
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
CN107106590B (zh) 2014-10-24 2022-10-18 阿斯利康(瑞典)有限公司 组合
RU2017119231A (ru) 2014-11-03 2018-12-06 Дженентек, Инк. Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
KR20170086540A (ko) 2014-11-03 2017-07-26 제넨테크, 인크. T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
RU2017119428A (ru) 2014-11-06 2018-12-06 Дженентек, Инк. Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
KR20170096112A (ko) 2014-11-17 2017-08-23 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
JP6744318B2 (ja) 2015-02-06 2020-08-26 ヒート バイオロジクス，インコーポレイテッド ワクチンおよび共刺激分子を共発現するベクター
EP3277305B1 (en) * 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
CA2981183A1 (en) 2015-04-07 2016-10-13 Greg Lazar Antigen binding complex having agonistic activity and methods of use
EA201792451A1 (ru) 2015-05-07 2018-05-31 Агенус Инк. Антитела к ox40 и способы их применения
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN108026158A (zh) * 2015-08-12 2018-05-11 免疫医疗有限公司 Gitrl融合蛋白及其用途
CA2997955A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
HRP20241752T1 (hr) 2015-09-25 2025-02-28 F. Hoffmann - La Roche Ag Anti-tigit protutijela i metode uporabe
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MX2018003820A (es) 2015-10-02 2018-12-10 F Hoffmann ­La Roche Ag Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
KR102833068B1 (ko) 2015-12-17 2025-07-14 노파르티스 아게 Pd-1에 대한 항체 분자 및 그의 용도
DK3400293T4 (da) 2016-01-08 2023-08-28 Replimune Ltd Modificeret onkolytisk virus
MX2018008310A (es) * 2016-01-11 2019-01-28 Inhibrx Inc Proteinas de fusion de union a ox40 multivalentes y multiespecificas.
ES3041500T3 (en) 2016-03-10 2025-11-12 Cg Oncology Inc Methods of treating solid tumors by combination therapy
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
EP3243836A1 (en) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
WO2018129332A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
JP2020516590A (ja) 2017-04-14 2020-06-11 コールド ジェネシス， インコーポレイテッド 膀胱癌の治療方法
US11377490B2 (en) * 2017-05-31 2022-07-05 Sichuan Clover Biopharmaceuticals, Inc Method for treating cancer using disulfide-linked trimeric 4-1BBL
WO2018226714A1 (en) 2017-06-05 2018-12-13 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
DK3710576T3 (da) 2017-11-17 2025-01-02 Iovance Biotherapeutics Inc Til-ekspansion fra finnålsaspirater og små biopsier
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
WO2019184909A1 (zh) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
US20210130779A1 (en) 2018-04-27 2021-05-06 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20210299187A1 (en) 2018-06-25 2021-09-30 Immodulon Therapeutics Limited Cancer therapy
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
SG11202101173TA (en) 2018-08-13 2021-03-30 Inhibrx Inc Ox40-binding polypeptides and uses thereof
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
WO2020061429A1 (en) 2018-09-20 2020-03-26 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
SG11202104663PA (en) 2018-11-05 2021-06-29 Iovance Biotherapeutics Inc Treatment of nsclc patients refractory for anti-pd-1 antibody
MX2021004953A (es) 2018-11-05 2021-08-11 Iovance Biotherapeutics Inc Seleccion de celulas t reactivas al tumor mejoradas.
US12343380B2 (en) 2018-11-05 2025-07-01 Iovance Biotherapeutics, Inc. Expansion of TILs utilizing AKT pathways inhibitors
CN113272421B (zh) 2018-11-05 2025-02-18 艾欧凡斯生物治疗公司 用于产生肿瘤浸润性淋巴细胞的方法及其在免疫疗法中的用途
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
JP7710372B2 (ja) 2018-12-19 2025-07-18 アイオバンス バイオセラピューティクス，インコーポレイテッド 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
WO2020176771A1 (en) 2019-02-27 2020-09-03 Ionis Pharmaceuticals, Inc. Modulators of malat1 expression
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4037693A1 (en) 2019-09-30 2022-08-10 Astrazeneca AB Combination treatment for cancer
US20220389381A1 (en) 2019-10-25 2022-12-08 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
AU2020391231A1 (en) 2019-11-27 2022-07-14 Turnstone Biologics Corp. Method of producing tumor-reactive T cell composition using modulatory agents
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
KR20220158727A (ko) 2020-02-27 2022-12-01 미스트 쎄라퓨틱스, 엘엘씨 종양 반응성 t 세포의 생체외 농축 및 확장 방법 및 이의 관련 조성물
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
EP4146794A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023552674A (ja) 2020-11-06 2023-12-19 イモデュロン セラピューティクス リミテッド がん治療のためのマイコバクテリア免疫療法
US20230405059A1 (en) 2020-11-10 2023-12-21 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
US20240131064A1 (en) 2020-12-11 2024-04-25 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
AU2022263418A1 (en) 2021-04-19 2023-10-26 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
CA3218590A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
JP2024529456A (ja) 2021-07-27 2024-08-06 イモデュロン セラピューティクス リミテッド がん治療における使用のためのＭｙｃｏｂａｃｔｅｒｉｕｍ
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
JP2025503987A (ja) 2022-01-28 2025-02-06 アイオバンス バイオセラピューティクス，インコーポレイテッド ペイロードを発現するように操作された腫瘍浸潤リンパ球
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
CN120737165A (zh) * 2024-09-29 2025-10-03 中国人民解放军总医院 一种可形成自组装三聚体的蛋白及其应用
CN120718109A (zh) * 2024-09-29 2025-09-30 中国人民解放军总医院 一类具备自组装聚性能的蛋白及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
GB9209032D0 (en) * 1992-04-25 1992-06-10 Ciba Geigy Ag New peptide derivatives
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6620413B1 (en) * 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6312700B1 (en) * 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US6828106B2 (en) * 1999-02-26 2004-12-07 Cyclacel Limited Methods and compositions using coiled binding partners
US7179468B1 (en) * 2000-06-08 2007-02-20 Cornell Research Foundation, Inc. Antigen for developing neutralizing antibodies to human immunodeficiency virus
CA2426659A1 (en) * 2000-10-24 2002-08-29 Immunex Corporation Method for treatment of tumors using combination therapy
ATE437891T1 (de) * 2000-12-07 2009-08-15 Lilly Co Eli Glp-1 fusionsproteine
US7238499B2 (en) * 2001-12-21 2007-07-03 Immunex Corporation Trimeric macrophage scavenger receptor fusion proteins and encoding nucleic acids
US20030224991A1 (en) * 2002-03-11 2003-12-04 Mohanraj Dhanabal Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis

Also Published As

Publication number Publication date
EP2650020B1 (en) 2016-08-24
SI1877090T1 (sl) 2014-12-31
PT2650020T (pt) 2016-12-12
EP1877090A2 (en) 2008-01-16
CY1118504T1 (el) 2017-07-12
DK2650020T3 (da) 2017-01-16
PT1877090E (pt) 2014-04-15
CA2606809C (en) 2016-01-05
PL2650020T3 (pl) 2017-07-31
SI2650020T1 (sl) 2017-03-31
CA2606809A1 (en) 2006-11-16
WO2006121810A2 (en) 2006-11-16
AU2006244497A8 (en) 2006-11-16
AU2006244497B2 (en) 2011-09-22
ES2605380T3 (es) 2017-03-14
EP2650020A1 (en) 2013-10-16
US20100136032A1 (en) 2010-06-03
US7959925B2 (en) 2011-06-14
AU2006244497A1 (en) 2006-11-16
EP1877090B1 (en) 2014-01-15
CY1119342T1 (el) 2018-02-14
US20060280728A1 (en) 2006-12-14
ES2457067T3 (es) 2014-04-24
LT2650020T (lt) 2016-12-12
HUE029789T2 (en) 2017-04-28
EP1877090A4 (en) 2009-07-29
WO2006121810A3 (en) 2007-03-29
PL1877090T3 (pl) 2015-04-30

Similar Documents

Publication Publication Date Title
DK1877090T3 (da) Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
DK1948852T3 (da) Hovedelektrode og fremgangsmåde til dannelse af hovedelektroden
DK1744590T3 (da) Høreapparat og tilsvarende fremgangsmåde til indstilling heraf
DK1844074T3 (da) Humane antistoffer og proteiner
DK1934179T3 (da) Fremgangsmåder og mellemprodukter
NO344992B1 (no) Anti-GM-CSF antistoffer og anvendelser for disse
DK1997291T3 (da) Metode og anordning til sikker godkendelse
DK1780295T3 (da) Svejseforbindelse og svejsemateriale deraf
DK1984344T3 (da) Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf
DK1968429T3 (da) Fremgangsmåde og system til stabilisering af sensorer
DK1973429T3 (da) Proteinhydrolysater og fremgangsmåde til fremstilling
NO20071302L (no) Bindingdomene fusjonsproteiner
DK1955102T3 (da) Fremgangsmåde og indretning til konfokal billedbehandling
DK1745075T3 (da) Poly-n-acetylglucosamin (pnag/dpnag)-bindende peptider og fremgangsmåder til anvendelse deraf
DK1871418T3 (da) Humaniserede anti-cd70-bindende midler og anvendelser deraf
DK2079355T3 (da) Fremgangsmåde og system til brilleordination
DK1965763T3 (da) Stabile enzympræparater og fremgangsmåder til anvendelse heraf
DK1868642T3 (da) Katte-allergenfusionsproteiner og anvendelser deraf
DK2029799T3 (da) Termostabile proteiner og fremgangsmåder til fremstilling og anvendelse heraf
EP1895838A4 (en) COMPOSITIONS AND METHODS
DK2066817T3 (da) Molekylære afbrydere og fremgangsmåder til anvendelse deraf
DK2479259T3 (da) Multi-kryokonserverede hepatocytter og fremgangsmåder til fremstillilng deraf
DK1919514T3 (da) Polynucleotider kodende for isoprenoid-modificerende enzymer og fremgangsmåder til anvendelse deraf
NO20054709D0 (no) Sammenfoyningssystem og anvendelse av dette
EP1934372A4 (en) SSB-POLYMERASE HYBRID PROTEINS